Companies:
50,705
Total Market Cap:
148169831903385.61
Global Rank
#17807
Country Rank
#649
Market Cap
317.39 M
Price
2.18
Change (%)
1.34%
Volume
431,352
PharmaEngine's latest marketcap:
317.39 M
As of 09/26/2025, PharmaEngine's market capitalization has reached $317.39 M. According to our data, PharmaEngine is the 17807th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 317.39 M |
| Revenue (ttm) | 81.32 M |
| Net Income (ttm) | 53.44 M |
| Shares Out | 143.68 M |
| EPS (ttm) | 0.37 |
| Forward PE | 28.20 |
| Ex-Dividend Date | 08/13/2025 |
| Earnings Date | 11/10/2025 |
Market Cap Chart
Data Updated: 09/26/2025
PharmaEngine's yearly market capitalization.
PharmaEngine has seen its market value drop from NT$29.2 B to NT$9.68 B since 2014, representing a total decrease of 66.83% and an annual compound decline rate (CAGR) of 9.77%.
| Date | Market Cap(NT$) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 09/26/2025 | NT$9.68 B | $317.39 M | -26.02% | 17807 |
| 12/31/2024 | NT$12.97 B | $395.06 M | -14.41% | 14552 |
| 12/29/2023 | NT$15.16 B | $493.09 M | -15.6% | 13086 |
| 12/30/2022 | NT$17.96 B | $586.42 M | 75.96% | 11248 |
| 12/30/2021 | NT$10.21 B | $368.18 M | 21.08% | 15234 |
| 12/31/2020 | NT$8.43 B | $299.69 M | -15.52% | 14569 |
| 12/31/2019 | NT$9.98 B | $333.07 M | -39.99% | 12175 |
| 12/28/2018 | NT$16.63 B | $543.08 M | -25.89% | 8710 |
| 12/29/2017 | NT$22.44 B | $755.01 M | 1.39% | 8422 |
| 12/30/2016 | NT$22.13 B | $681.13 M | -9.76% | 8229 |
Company Profile
About PharmaEngine, Inc.
PharmaEngine, Inc. is a biopharmaceutical company focused on developing innovative drugs for cancer treatment. Headquartered in Taipei, Taiwan, the company was established in 2002 and specializes in oncology therapeutics.
Key Products and Developments
- ONIVYDE: A cancer medicine that inhibits topoisomerase I, an enzyme critical for DNA replication in cancer cells.
- PEP07: A CHK1 inhibitor currently in Phase 1 clinical trials for treating hematological and solid tumors.
PharmaEngine is committed to advancing cancer therapies through cutting-edge research and clinical development.
Frequently Asked Questions
-
What is PharmaEngine's (TPEX-4162) current market cap?As of 09/26/2025, PharmaEngine (including the parent company, if applicable) has an estimated market capitalization of $317.39 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does PharmaEngine (TPEX-4162) rank globally by market cap?PharmaEngine global market capitalization ranking is approximately 17807 as of 09/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.